Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Gross Margin: 2012-2025

Historic Gross Margin for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to 59.01%.

  • Ani Pharmaceuticals' Gross Margin rose 153.00% to 59.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 61.14%, marking a year-over-year increase of 135.00%. This contributed to the annual value of 59.27% for FY2024, which is 344.00% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Gross Margin stood at 59.01%, which was down 8.80% from 64.70% recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Gross Margin ranged from a high of 64.70% in Q2 2025 and a low of -78.44% during Q1 2021.
  • For the 3-year period, Ani Pharmaceuticals' Gross Margin averaged around 61.43%, with its median value being 62.95% (2025).
  • In the last 5 years, Ani Pharmaceuticals' Gross Margin tumbled by 13,463bps in 2021 and then spiked by 12,529bps in 2022.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Gross Margin stood at 44.36% in 2021, then skyrocketed by 1,709bps to 61.45% in 2022, then slumped by 203bps to 59.42% in 2023, then plummeted by 155bps to 57.87% in 2024, then surged by 153bps to 59.01% in 2025.
  • Its last three reported values are 59.01% in Q3 2025, 64.70% for Q2 2025, and 62.95% during Q1 2025.